FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Indication

Blood Cancers

Clinical and regulatory intelligence for Blood Cancers with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Relevant assets

NCI →

Relevant companies

No related entities indexed yet.

Recent signals(1)

ClinicalAugust 11, 2026

NCI Launches Study on Tailored Stem Cell Transplantation for RUNX1 Blood Cancers

The National Cancer Institute (NCI) has initiated a prospective trial to assess the efficacy of tailored chemotherapy and supportive care in stem cell transplantation for patients with blood cancers linked to germline RUNX1 mutations.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Blood Cancers →

Hematology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.